Channels Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis
The Plasma, Whole Blood and Intracellular Concentrations of Antiretroviral Agents in South African Children Receiving Combination Antiretroviral Therapy with and without Concomitant Antitubercular Treatment
The pharmacokinetics of lopinavir in HIV-infected adults receiving rifampicin with adjusted doses of lopinavir
Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs
Simultaneous quantification of first-line anti-tuberculosis drugs and metabolites in human plasma
Characterizing population pharmacokinetic/pharmacodynamic relationships in pulmonary tuberculosis infected adults using nonlinear mixed effects modelling
Liver Injury in HIV-positive Patients on Antituberculosis and/or Antiretroviral Therapy – Assessing Causality
Development and validation of liquid chromatography mass spectrometry (L/C/MS/MS) assay for the determination of plasma 4betahydroxycholestrol and cholesterol in HIV infected children in Africa
Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
Determinants and consequences of the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in a cohort of tuberculosis patients
Determination of total, unbound, and intracellular concentrations of the antiretroviral drugs Efavirenz, Lopinavir, and Ritonavir
Pharmacogenomics and pharmacokinetics of antiretroviral drugs and their associations with metabolic complications in HIV-infected Black South Africans
Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy
Clinical, pharmacokinetic, and genetic determinants of change in serum creatinine among Southern Africans on dolutegravir based antiretroviral therapy
Antiretroviral therapy adherence and effectiveness in a private sector disease management programme in Southern Africa
Pharmacogenomics and pharmacokinetics of dolutegravir and tenofovir in Southern Africans living with HIV
Addressing challenges in the treatment of tuberculosis and tuberculosis meningitis: a pharmacometric approach
Population pharmacokinetic modelling to address the gaps in knowledge of commonly used HIV and TB drugs in children
Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
Effect of dihydroartemisin-piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV
Pharmacogenetics of Tenofovir (Alafenamide or Disoproxil Fumarate Prodrug) Renal Toxicity in HIV positive Black Southern Africans
A mixed method study of the factors influencing the validity of medical and medication histories obtained from potential healthy adult clinical trial participants
Self-Reported Antenatal Medicines Use Among Women Living with and Without HIV in Western Cape, South Africa: A Sub-Analysis of the B Positive Cohort Study
